Staying #Up2Date 🚨

1: Real-world safety signals with roflumilast
A pharmacovigilance analysis using US and Canadian adverse event databases found roflumilast was most commonly linked to respiratory, psychiatric, and general disorders, including cough, dyspnea, tachycardia, and symptom aggravation. Many events occurred within the first 30 days of treatment, and patterns varied by sex and formulation. The findings highlight the need for early monitoring and proactive patient counselling when starting therapy.

2: Red blood cells and cardiovascular risk in long-standing T2D
A study of 112 adults with Type 2 diabetes found that changes in red blood cells — particularly lower miRNA‑210‑3p levels — were linked to endothelial dysfunction and higher cardiovascular risk, especially in patients with longer disease duration. The results suggest that RBC‑based biomarkers could help identify patients at highest risk for vascular complications and guide earlier intervention.

Bepirovirsen shows breakthrough potential in chronic hepatitis B
In a phase 2b trial of 369 adults with chronic hepatitis B, adding bepirovirsen — an antisense oligonucleotide — to standard antiviral therapy led to significant declines in viral markers, including surface antigen levels, compared with standard treatment alone. The effect was most pronounced in patients not previously on nucleos(t)ide therapy, suggesting this approach could move the field closer to a functional cure. Safety was consistent with expectations, and researchers say the results support further study of bepirovirsen as a potential step toward durable viral control.

Weight Loss On Lease 💉

The tiny print in GLP-1 contracts that nobody wants to read

What happened: A new study from the University of Oxford found people who stopped taking weight loss drugs like Ozempic regained most of the weight within just 2 years. 

Why it matters: This was no small trial. Researchers at the University of Oxford reviewed randomized trials and observational studies of more than 6,000 adults taking GLP-1s or other weight-loss medications, and compared them with about 3,000 people enrolled in behavioural weight-management programs. After stopping treatment, participants regained about 0.4 kg/month — roughly 4.5 kg in the first year. 

While some patients may be surprised by the findings, their doctors likely aren’t. One physician compared obesity treatment to hypertension: once the drugs start working, the underlying condition doesn’t just go away. GLP-1 drugs work largely by suppressing appetite. When the medication stops, that effect does too — and fast.

But: Hunger isn’t the only post-GLP-1 concern for patients. The analysis found a reversal in cardiovascular benefits, including improvements in heart disease and high cholesterol levels. Also diabetes control, which returned to pre-treatment levels in less than 2 years.

One researcher involved in the study said semaglutide was linked to greater weight loss when paired with support, like dieticians, who could help them cope with hunger pangs.

Bottom line: The research answers one question clearly: what happens after people stop GLP-1s. But it leaves many unanswered, too, like why weight returns so quickly and whether lower-dose treatments might help. For now, the information is observational, and the evidence is still evolving.

Hot Off The Press

1: 🧪 Cholesterol drugs vs. aggressive breast cancer? Recent research suggests pitavastatin, a common statin, may target chemotherapy-resistant triple-negative breast cancer cells by suppressing stem-like tumour cells and blocking the survival protein Mcl‑1. Early lab results show it can enhance chemo effects, offering a potential repurposing opportunity. Pharmacists should watch this space: if clinical trials confirm safety and dosing, statins could have a future beyond heart health.

2: 🦠 A surprising flu experiment showed that even when healthy adults spent days indoors with people sick with influenza, none of them got infected. In a controlled study, low coughing rates and well-mixed indoor air meant virus particles didn’t build up to infectious levels, suggesting that simple steps like improving ventilation and reducing face-to-face exposure could sharply cut flu spread. Researchers say masks and air movement may be key tools this season, especially in crowded indoor settings.

3: 🥗 Canada’s new front-of-package nutrition labels are now in force — Health Canada’s updated rules require a bold “high in” symbol on pre‑packaged foods that exceed thresholds for saturated fat, sugars, or sodium, making it easier for consumers to spot nutrition risk at a glance. Early expert reactions suggest the prominent icons are very effective at changing purchase behaviour.

4: 🤖 ChatGPT and Claude are officially scrubbing in. OpenAI and Anthropic both announced new health-focused tools this month, framing their chatbots as ways to explain lab results, summarize medical records, and help patients prepare for appointments. Experts warn the tools aren’t clinically validated and often fall outside health-privacy laws. The AI companies are stressing their bots aren’t meant to replace, but that won’t stop AI — and its questionable health tech gadgets — from entering exam rooms, whether clinicians invite it or n

Shelf Watch 🏪

⚠️ Drug Shortages

• Bicillin L‑A: Penicillin G injections still limited; alternatives may be needed.

• Trandolapril 0.5–1 mg: ACE inhibitor; anticipated shortage, may need alternative dosing.

• Rocuronium Bromide Injection 10 mg: Neuromuscular blocker for anesthesia; anticipate sourcing challenges.

🎉 Newly Approved Drugs

• Bepirovirsen – Phase 2b Hep B therapy shows viral suppression.

• Rivaroxaban (generic) – Expands access for anticoagulation.

• India‑sourced Ozempic – Affordable US option; pharmacists field safety questions.

Postcall Picks ✅

🎙️ Listen: to The Pharmacy Podcast Tech Trends with Dr. Matthew Song — learn how data and automation can make your pharmacy workflow smoother, safer, and smarter.

🍲 Make: this cozy, cheesy chicken tortilla soup — tender chicken, black beans, corn, and soft tortilla strips — for a comforting weeknight meal.

🌴 Visit: a tucked-away Caribbean island with high-end hotels, quiet beaches, and small towns worth wandering.

😂 Laugh: at this comic many pharmacists are all too familiar with — deciphering doctor handwriting.

Taking the Pulse 🫀

We want to ask: 

Relax

First clue: Can be whipped or iced or applied to the skin

Need a rematch? We’ve got you covered. Check out our Crossword Archive to find every puzzle we’ve ever made, all in one place.

Think you crushed it? Challenge your physician friends to beat your time.

Meme of the Week

Help Us Get Better